Price trajectories assessment for Medicare Part B generic anti-cancer drugs.

• DOI: 10.1200/jco.2017.35.15_suppl.6624
• Publication Date: 2018-09-06T15:47:44Z
• Authors: Noa Gordon; Omer Ben-Aharon; Salomon M. Stemmer; Dan Greenberg; Daniel A. Goldstein
• Keywords: Drug prices; Cancer drugs; Expiration date

6624 Background: Patented anti-cancer drugs launch prices have increased in recent years with subsequent increases after launch. Recently, large price of generic were at the center public attention United States. Our aim was to assess changes time for Medicare part B and understand how drug characteristics market structure influence trajectories. Methods: We included all reported both 2006 2016. Patent expiration dates attached using Drug Expiration engine a patent date later than excluded. Generic manufacturers' FDA approvals each extracted from Orange Book. For we Average Sales Price (ASP) history October 2016, published by Center Medicaid services (CMS). Prices adjusted inflation, information obtained States Department Labor. calculated cumulative ASP change during follow-up period. Data analyzed IBM SPSS Statistics software. Results: identified 31 that met inclusion exclusion criteria. During period, 15 (48%) had (median 139%, range 18-2632%). Seven (23%) more 200% (Table 1). Both gradual acute observed. Some which substantial no competition market. Conclusions: may substantially time. Gradual or rapid be due lack competition, substitution shortages marketing reasons. New regulations needed prevent further costs, while balancing need maintain financial incentives production competition. [Table: see text]